Imagine a baby born too early whose stomach is like an unfinished puzzle—it can't yet absorb the food it needs to grow. Instead of relying on risky IV drips, this treatment uses a special form of insulin that acts like a 'jump-start' for the gut. It helps the digestive system mature faster so the baby can start eating normally much sooner.
Preterm infants often cannot absorb nutrients, forcing reliance on risky central line nutrition. This leads to longer hospital stays and a high risk of life-threatening infections.
A GMP-manufactured oral insulin-based drug and the complete clinical trial infrastructure, including submission packages and site contracts.
If you are a drug manufacturer dealing with a lack of treatments for orphan neonatal diseases — this project developed an oral insulin-based medication that is safe and effective. It targets infants born before 32 weeks of gestation to accelerate GI development.
If you are a NICU operator dealing with high bed-occupancy and infection risks — this project developed a therapy that reduces hospitalization by ~7 days and cuts life-threatening infections by 40%.
If you are a distributor dealing with the need for high-standard neonatal drug delivery — this project developed a GMP-manufactured, labeled, and packaged drug product ready for phase III clinical trials.
Based on available project data, the specific price per dose or treatment cost is not mentioned.
The project successfully completed GMP manufacturing, including active medication and placebo, with qualified analytical laboratories for release and stability testing.
Based on available project data, specific patent or licensing details are not provided, though the drug is being prepared for marketing authorization filing.
The project has completed preparations for the final phase III trial, which is the last study required before filing for marketing authorization.
It replaces or reduces the duration of parenteral nutrition (central line nutrition) by stimulating the gut to transition to oral nutrition faster.
The project is led by a single Israeli SME, Elgan Pharma Ltd. This 100% industry-led structure indicates a highly focused commercial drive, avoiding the typical delays of academic-industrial partnerships and moving directly toward clinical validation and market entry.
Contact Elgan Pharma Ltd. regarding the upcoming phase III trial results.
Contact us to explore licensing opportunities for this neonatal GI therapy.
